Last Updated : September 17, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Received
Therapeutic Area:
Non-Small Cell Lung Cancer, neoadjuvant
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0385-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Keytruda (pembrolizumab)
is indicated for the treatment of adult patients with resectable stage II,
IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum containing
chemotherapy as neoadjuvant treatment, and then continued as monotherapy as
adjuvant treatment.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Keytruda (pembrolizumab) is indicated for the treatment of adult patients with resectable stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum containing chemotherapy as neoadjuvant treatment, and the continued as monotherapy as adjuvant treatment
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 06, 2024 |
|---|---|
| Call for patient/clinician input closed | September 27, 2024 |
| Submission received | September 17, 2024 |
| Submission accepted | - |
Last Updated : September 17, 2024